UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Monoclonal antibody-based therapies in cancer: Advances and challenges

Pharmacology & therapeutics (Oxford), 2013-06, Vol.138 (3), p.452-469

2013

Volltextzugriff (PDF)

Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?

Biochemical pharmacology, 2016-02, Vol.102, p.1-6

2016

Volltextzugriff (PDF)

The Next Generation of Antibody Drug Conjugates

Seminars in oncology, 2014-10, Vol.41 (5), p.637-652

2014

Volltextzugriff (PDF)

A general approach to site-specific antibody drug conjugates

Proceedings of the National Academy of Sciences - PNAS, 2014-02, Vol.111 (5), p.1766-1771

2014

Volltextzugriff (PDF)

Advances in bispecific biotherapeutics for the treatment of cancer

Biochemical pharmacology, 2012-11, Vol.84 (9), p.1105-1112

2012

Volltextzugriff (PDF)

Antibody-drug conjugates: an emerging modality for the treatment of cancer

Annals of the New York Academy of Sciences, 2014-08, Vol.1321 (1), p.41-54

2014

Volltextzugriff (PDF)

Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers

Bioconjugate chemistry, 2008-04, Vol.19 (4), p.849-859

2008

Volltextzugriff (PDF)

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

PloS one, 2017-05, Vol.12 (5), p.e0178452-e0178452

2017

Volltextzugriff (PDF)

Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model

Clinical cancer research, 2008-03, Vol.14 (6), p.1888-1896

2008

Volltextzugriff (PDF)

Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia

Neoplasia (New York, N.Y.), 2018-01, Vol.20 (1), p.1-11

2018

Volltextzugriff (PDF)

Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography

Molecular cancer therapeutics, 2016-10, Vol.15 (10), p.2530-2540

2016

Volltextzugriff (PDF)

Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor

Clinical cancer research, 2010-10, Vol.16 (19), p.4809-4821

2010

Volltextzugriff (PDF)

Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes

Clinical cancer research, 2004-04, Vol.10 (7), p.2530-2537

2004

Volltextzugriff (PDF)

Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model

mAbs, 2021, Vol.13 (1), p.1958662-1958662

2021

Volltextzugriff (PDF)

Preclinical Development of an anti-5T4 Antibody–Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice

Bioconjugate chemistry, 2015-11, Vol.26 (11), p.2223-2232

2015

Volltextzugriff (PDF)

Ligand-targeted liposomes for cancer treatment

Current drug delivery, 2005-10, Vol.2 (4), p.369

2005

Volltextzugriff (PDF)

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

Journal of pharmacokinetics and pharmacodynamics, 2013-10, Vol.40 (5), p.557-571

2013

Volltextzugriff (PDF)

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors

mAbs, 2021-01, Vol.13 (1), p.1850395

2021

Volltextzugriff (PDF)

Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia

Haematologica (Roma), 2017-06, Vol.102 (6), p.1075

2017

Volltextzugriff (PDF)

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2309-2319

2011

Volltextzugriff (PDF)

Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments

Clinical cancer research, 2004-02, Vol.10 (3), p.1100-1111

2004

Volltextzugriff (PDF)

Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

Clinical cancer research, 2005-07, Vol.11 (14), p.5257-5264

2005

Volltextzugriff (PDF)

NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells

Cell reports. Medicine, 2021-05, Vol.2 (5), p.100279-100279, Article 100279

2021

Volltextzugriff (PDF)

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

Pharmaceutical research, 2015-11, Vol.32 (11), p.3494-3507

2015

Volltextzugriff (PDF)

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

Molecular immunology, 2015-10, Vol.67 (2), p.107-116

2015

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(95)

Publikationsform

Sprache

Englisch
(101)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(45)
Humans
(44)
Animals
(39)
Mice
(30)
Oncology
(29)
Cell Line, Tumor
(23)
Female
(18)
Antineoplastic Agents - Pharmacology
(12)
Mice, Nude
(12)
Xenograft Model Antitumor Assays
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Immunoconjugates - Pharmacokinetics
(10)
Immunoconjugates - Pharmacology
(10)
Neoplasms - Drug Therapy
(10)
Pharmacology & Pharmacy
(10)
Antineoplastic Agents - Therapeutic Use
(9)
Immunoconjugates - Therapeutic Use
(9)
Antineoplastic Agents
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(27)
Molecular Cancer Therapeutics
(14)
Clinical Cancer Research
(11)
Blood
(9)
Bioconjugate Chemistry
(3)
Angiogenesis
(2)
Biochemical Pharmacology
(2)
Cellular & Molecular Biology Letters
(2)
Haematologica
(2)
Mabs
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Monoclonal antibody-based therapies in cancer: Advances and challenges

Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?

The Next Generation of Antibody Drug Conjugates

A general approach to site-specific antibody drug conjugates

Advances in bispecific biotherapeutics for the treatment of cancer

Antibody-drug conjugates: an emerging modality for the treatment of cancer

Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model

Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia

Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography

Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor

Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes

Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model

Preclinical Development of an anti-5T4 Antibody–Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice

Ligand-targeted liposomes for cancer treatment

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors

Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments

Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

Suchergebnisse filtern